K. E. Goldstein

发表

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

Robert P. Anderson, Glenn O. Brown, A. Coates, 2020, BMC Medicine.

A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease

L. Williams, M. Y. Hardy, J. Tye-Din, 2021, Frontiers in Immunology.

Elevated serum interleukin‐2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease

S. Acaster, J. Macdougall, J. Tye-Din, 2019, Alimentary pharmacology & therapeutics.

Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity

K. Lundin, L. Sollid, G. Skodje, 2020, United European gastroenterology journal.

Long-term phorbol ester treatment dissociates phospholipase D activation from phosphoinositide hydrolysis and prostacyclin synthesis in endothelial cells stimulated with bradykinin.

T. W. Martin, J. Wagner, K. E. Goldstein, 1989, Biochemical and biophysical research communications.

Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet

Glenn O. Brown, M. Mäki, B. Lebwohl, 2020 .

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.

R. Xavier, J. Sidney, A. Sette, 2017, The lancet. Gastroenterology & hepatology.

Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease

L. Williams, J. Tye-Din, K. Truitt, 2019, Alimentary pharmacology & therapeutics.

Whole blood interleukin‐2 release test to detect and characterize rare circulating gluten‐specific T cell responses in coeliac disease

L. Williams, M. Y. Hardy, J. Tye-Din, 2021, Clinical and experimental immunology.

Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease

R. Xavier, L. Sollid, S. Qiao, 2019, Science Advances.

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

J. Andrews, R. Gearry, G. Holtmann, 2023, The lancet. Gastroenterology & hepatology.

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

J. Andrews, J. Macdougall, L. Williams, 2017, EBioMedicine.

579: SAFETY, TOLERABILITY AND PHARMACODYNAMIC ASSESSMENT OF KAN-101, A NOVEL LIVER-TARGETED THERAPY TO INDUCE IMMUNOLOGICAL TOLERANCE TO GLIADIN IN CELIAC DISEASE

J. Murray, R. Manchanda, K. Grebe, 2022, Gastroenterology.

Serum IL-2 and IL-8 are Elevated within 4 h after Gluten Ingestion in Celiac Disease (CED) Patients on Gluten-Free Diet (GFD) and Potential to Resolve Indeterminate Diagnoses for Patients on GFD

L. Williams, J. Tye-Din, Suyue Wang, 2017 .

Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.

J. Murray, K. Grebe, Dina Wassaf, 2023, The lancet. Gastroenterology & hepatology.